Spain’s largest drugmaker Almirall (ALM: MC) yesterday announced results for the first quarter of 2011, saying it is on track to attain the yearly financial guidance. As of March 31, net sales dropped 12.3% to 212.7 million euros ($308.6 million) with stable evolution of the international business in Europe (+0.1%), and lower performance from the domestic business (-14.0%).
Sales were materially affected by the uneven year-on-year comparison. While the first quarter of 2010 was not yet impacted by the two health care reforms in Spain, the first quarter was fully impacted by the price erosion linked to these reforms. Generic competition has also hindered sales performance, especially in the case of Prevencor (atorvastatin), sales of which plunged nearly 42% to 13.2 million euros.
Gross Profit stood at 132.9 million euros (62.5% of sales) reflecting the unfavorable impact of the mandatory discount of 7.5% on patented products implemented in Spain in mid 2010. Despite this, gross margin in the quarter as a percentage on sales was improved vs FY 2010 (61.9%). Both EBIT and EBITDA pulled back to 37.9 million euros (-39.7%) and 53.3 million euros (-31.8%) respectively in a context material sales drop due to price erosion and generic competition. In this context, net income reached 30.6 million euros (-40%). Yearly guidance is confirmed and normalized net income (net income less non recurrent elements) is expected to decline by a mid-teen percentage, said Almirall.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze